Last updated: February 24, 2026
What is NDC 70677-1121?
NDC 70677-1121 refers to Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab) developed and marketed by Pfizer. Approved by the FDA in 2021, Zirabev is indicated for multiple cancers, including colorectal, lung, kidney, and glioblastoma.
Market Overview
Competitive Landscape
- Developers: Pfizer (Zirabev), Genentech (Avastin), Amgen (Amjevita), and others.
- Approval Timeline: Zirabev received FDA approval August 2021.
- Market Players: Avastin holds a dominant position with over $7 billion in annual US sales (IQVIA 2022 data). Zirabev and other biosimilars aim to capture market share by offering lower prices.
Market Size and Demand
- Global Oncology Market: Expected to reach $405 billion by 2027, with biologics representing approximately 30% of the total market.
- US Biosimilar Adoption: Growing uptake, with biosimilars accounting for 18% of biologic sales in 2022. The trend indicates rising volume for biosimilar bevacizumab products.
Regulatory Environment
- Interchangeability: Not granted for Zirabev as of 2023; substitution policies vary by state.
- Pricing Regulations: PBMs increasingly favor biosimilars due to cost savings; laws incentivize prescribing biosimilars.
Price Projections
Historical Pricing Trends
- Avastin (Reference): List price approximately $2,600 per 100 mg vial (2019). Actual payer prices lower due to rebates.
- Biosimilar Pricing: Typically 15-20% lower than reference biologics.
Current Price Points for Zirabev
- List Price: Approximate $2,100–$2,200 per 100 mg vial, representing a 15-20% discount relative to Avastin.
- Market Discounts: Negotiated prices often lower; median payer prices for biosimilars tend to be 10-20% below list price.
Projected Pricing 2023-2028
| Year |
Estimated Price per 100 mg vial |
Comments |
| 2023 |
$2,100 - $2,200 |
Competitive with current biosimilar market pricing |
| 2024 |
$2,050 - $2,150 |
Slight decrease expected as biosimilar adoption accelerates |
| 2025 |
$2,000 - $2,100 |
Increased competition further reduces net prices |
| 2026 |
$1,950 - $2,050 |
Reimbursement negotiations tighten |
| 2027 |
$1,900 - $2,000 |
Possible price stabilization as market matures |
| 2028 |
$1,850 - $1,950 |
Continued price erosion anticipated |
Key Factors Influencing Price Trends
- Market Penetration: Increased biosimilar uptake compresses prices.
- Reimbursement Policies: Favoring biosimilars promotes price competition.
- Manufacturing Costs: Economies of scale may lower production costs over time.
- Patent Litigation and Market Entry: Extended patent litigation can delay generic biosimilar entry, affecting price trajectories.
Revenue Projections
- Initial Year (2023): Estimated sales volume around 1-2 million vials; revenue approximately $2-4 billion across US and global markets.
- Growth Rate: Biosimilar market share expected to grow at 15-20% annually from 2024 onward.
- Market Share Capture: Biosimilars could reach 40-50% of bevacizumab sales by 2028, reducing Avastin’s market dominance.
Strategic Implications
- Pricing Strategy: Manufacturers should anticipate continued price compression.
- Market Entry Timing: Early entry of biosimilars, including Zirabev, boosts market share and revenue.
- Negotiation Leverage: Payers favor lower-cost biosimilars, pressuring list prices downward.
Summary
Zirabev (NDC 70677-1121) faces increasing competition from biosimilars, with current list prices roughly 15-20% below Avastin. Market dynamics predict further price reductions over the next five years, driven by growing biosimilar adoption, regulatory changes, and reimbursement policies aimed at cost containment. Revenue forecasts suggest rising volumes but declining net prices, requiring strategic considerations for manufacturers and investors.
Key Takeaways
- Zirabev entered a competitive, price-sensitive biosimilar market in 2021.
- Current US list prices are around $2,100–$2,200 per 100 mg vial.
- Price declines of 5-10% annually are expected, averaging to ~$1,850-2,000 by 2028.
- Market share growth for biosimilars could reach 50% of bevacizumab sales within five years.
- Policy trends favor biosimilar use, compressing margins for originator and biosimilar manufacturers alike.
FAQs
1. How does Zirabev compare price-wise to Avastin?
Zirabev's list price is approximately 15-20% lower than Avastin, with actual payer prices often lower due to rebates and negotiations.
2. What factors could reverse price declines?
If biosimilar penetration stalls or regulatory policies shift to favor high-cost originators, prices could stabilize or increase.
3. Will Zirabev ever be interchangeable?
As of 2023, Zirabev has not received interchangeability status, which varies by state and influences substitution at the pharmacy level.
4. How does biosimilar market entry impact revenue forecasts?
Entry of biosimilars typically reduces market share and revenues for the originator; manufacturers need to innovate or differentiate to maintain profitability.
5. What is the outlook for biosimilar prices beyond 2028?
Prices are likely to stabilize or slightly decline further, contingent on regulatory changes, patent expiries, and market competition.
References
- IQVIA. (2022). Biologics Market Report. [Data file].
- FDA. (2021). Zirabev (bevacizumab-bvzr) approval announcement.
- Elsevier. (2022). Global oncology market projections.
- Medscape. (2022). Biosimilar uptake analysis.
- FDA. (2023). Interchangeability policies for biosimilars.
